Early Study Shows Cabazitaxel May Be More Effective Than Docetaxel in Some Patients With Advanced Prostate Cancer
In a new study reported by de Leeuw et al in Clinical Cancer Research, researchers found that the novel taxane cabazitaxel (Jevtana) has properties that could make it more effective than docetaxel in some patients with advanced prostate cancer. This hypothesis is currently being tested in a phase II clinical trial. Researchers have also found a genomic marker that could help physicians identify which patients might benefit most from cabazitaxel.
“It was surprising to find that cabazitaxel functions differently than docetaxel in killing cancer cells, even though they’re both taxanes,” said senior author Karen Knudsen, PhD, Interim Director of the Sidney Kimmel Cancer Center and Professor of Cancer Biology at the Sidney Kimmel Medical College at Thomas Jefferson University. “It shows that we may not be taking full advantage of this next-generation taxane in the clinic.”
Cabazitaxel vs Docetaxel
For years, docetaxel has been the only effective chemotherapy for men whose prostate cancer was no longer responding to hormone treatments. The next-generation drug in the taxane family, cabazitaxel, was approved by the U.S. Food and Drug Administration (FDA) in 2010, but only for patients whose prostate cancer no longer responded to hormone therapy or docetaxel treatment.
Dr. Knudsen and colleagues explored how cabazitaxel worked and demonstrated that it might be more effective sooner in treatment. The researchers showed that cabazitaxel worked better than docetaxel in human prostate cancer cells lines that were resistant to hormone treatment, both in terms of slowing growth of cancer cells and in its ability to kill cancer cells.
Analysis of the tumor genes affected by the two drugs revealed that cabazitaxel had a greater effect on cellular division and regulation of chromatin, whereas docetaxel had a greater impact on DNA transcription and repair. “This difference in mechanism suggests that we should treat these two drugs less like members of the same family and more like two distinct therapies that may each have distinct benefits for certain patients,” said first author Renée de Leeuw, a postdoctoral researcher in the Department of Cancer Biology at Thomas Jefferson University.
To test their hypothesis in a model that more closely mimicked human disease, the researchers also tested the two drugs side-by-side on slices of tumors removed from patients during radical prostatectomy. The tissues were grown on a three-dimensional gelatin sponge, and two portions of the same tumor were treated with either cabazitaxel or docetaxel. The results confirmed that cabazitaxel was more effective at killing tumor cells than docetaxel.
New Biomarker for Taxane Responsiveness
The collaborative research team also found a molecular marker that would help identify patients most likely to benefit from cabazitaxel treatment. Dr. Knudsen and colleagues showed that tumors whose retinoblastoma gene (RB) no longer worked were likely to become hormone resistant but remarkably were more likely to respond to cabazitaxel. “This gene could give us a way to identify patients who would benefit from cabazitaxel earlier and reduce the trial and error of treating a cancer patient,” says Dr. Knudsen.
Dr. Knudsen and W. Kevin Kelly, DO, Professor of Medical Oncology, Thomas Jefferson University Hospital, are testing their hypothesis in a phase II clinical trial (ABICABAZI; NCT02218606), which is currently recruiting patients. The study is funded by Sanofi and is a collaboration between Sidney Kimmel Cancer Center and Memorial Sloan Kettering Cancer Center. Patients with metastatic prostate cancer who have not yet been treated with chemotherapy will be given either the second-line hormone therapy abiraterone (Zytiga) or abiraterone in combination with cabazitaxel. In addition, researchers will scan the tumors for their RB gene expression, to test whether low levels of RB correlate with strong responses to cabazitaxel.
“These results from our laboratory research give us a strong reason to believe that this drug could be more useful to some men earlier in their course of treatment,” said Dr. Knudsen. “The ABICABAZI trial puts these ideas to the test in humans, and if we are correct, has the capacity for the first time to tell us what patients might most benefit from chemotherapy.”
Dr. Knudsen is the corresponding author of the Clinical Cancer Research article.
This study was supported by the Department of Defense, the National Institutes of Health, the Prostate Cancer Foundation Young Investigator Award, Sanofi-Aventis, and the Commonwealth of Pennsylvania Cure.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
